Related Experiment Videos
[FOLFOX].
Hideyuki Mishima1, Masakazu Ikenaga, Toshimasa Tsujinaka
1National Hospital Organization, Osaka National Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 13, 2006
Summary
The FOLFOX chemotherapy regimen for metastatic colorectal cancer can cause limiting toxicities like neutropenia and neurotoxicity. Careful attention to these side effects is crucial for patient treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Cancer Treatment
Context:
- Metastatic colorectal cancer (mCRC) treatment landscape.
- FOLFOX (Leucovorin, fluorouracil, oxaliplatin) as a standard first-line therapy.
- Significant toxicities associated with FOLFOX chemotherapy.
Purpose:
- To highlight the primary toxicities of the FOLFOX regimen.
- To emphasize the clinical significance of neutropenia and oxaliplatin-induced neurotoxicity.
- To underscore the importance of monitoring for hypersensitivity reactions.
Summary:
- FOLFOX is a common first-line treatment for metastatic colorectal cancer.
- Key dose-limiting toxicities include neutropenia and reversible sensory neuropathy from oxaliplatin.
- Cumulative neurotoxicity can necessitate treatment cessation.
- Immediate hypersensitivity reactions (anaphylaxis) occur in up to 0.6% of patients.
Impact:
- Increased awareness of FOLFOX side effects is necessary for effective mCRC management.
- Understanding toxicities can guide treatment modifications and supportive care.
- Minimizing adverse events can improve patient adherence and therapeutic outcomes.